This organization files Form 990, which has no section for application policy. Its filings cannot say either way.
The latest filing we hold carries no statement about applications. That is not the same as closed: public-charity Form 990s have no field for it, and many foundations leave the section blank.
Grants paid by year
Total assets by year
Where the money went · FY2024
Form 990 splits expenses into program services, management and fundraising. The split is self-reported, and a grantmaker, a research institute and a direct-service nonprofit book the same work differently. A line the return does not carry reads "not available"; it is never counted as zero.
| Year | Form | Revenue | Expenses | Grants paid | Assets | Net assets |
|---|---|---|---|---|---|---|
| FY2024 | 990 | $69,628 | $135,928 | $129,934 | $776,581 | $718,502 |
| FY2023 | 990 | $52,140 | $252,639 | $247,857 | $814,715 | $743,740 |
| FY2022 | 990 | $104,640 | $255,319 | $242,738 | $965,576 | $865,577 |
| FY2021 | 990 | $183,014 | $139,882 | $132,610 | $1,296,631 | $1,289,609 |
| FY2020 | 990 | $74,344 | $196,561 | $178,775 | $1,222,644 | $1,212,932 |
Figures are as reported on the e-filed return, with no restatement. Fiscal years are the funder's own tax year, labelled by the calendar year the period ends in. A blank line means the return does not carry that figure; a real zero shows as $0. When an amended return replaces an original, every figure here uses the amended return. The original is not shown. Giving is what the funder actually paid out toward its charitable purpose in the year (qualifying distributions on Form 990-PF, charitable disbursements otherwise). Assets are what it holds; giving is what moves.
Recipient focus areas
Where recipients are
Based on the 100% of grant rows we could match to an organization record. The rest stay as reported. The IRS assigns the NTEE category when it grants exemption. It often reflects the original filing, not today's giving.
| Recipient | Purpose | Amount | Year | Source |
|---|---|---|---|---|
| MEMORIAL SLOAN KETTERING CANCER CENTERNEW YORK, NY | SUPPORTED RESEARCH ON EYE CANCER PERFORMED AT MSKCC: STUDIES ON CELL FREE DNA IN PLASMA OF RETINOBLASTOMA PATIENTS, STUDIES OF CHOROIDAL INVASION IN RETINOBLASTOMA, STUDIES OF THE USE OF INTRARTERIAL CHEMOTHERAPY IN HISTIOCYTOSIS, STUDIES ON EFFICACY AND TOXICITY OF INTRAVITREAL TOPOTECAN FOR EYE CANCER. | $198,692 | 2023 |
Recipients are shown as the funder wrote them on the return. A recipient with a link was matched to an organization record; the rest stay as reported and are never guessed.
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| David H Abramson Md | DIRECTOR & PRESIDENT | 1.00 | $0 |
| Allan Abramson Md | DIRECTOR | 0.30 | $0 |
| Nicholas Grumbach Md | DIRECTOR | 0.20 | $0 |
| Hilary Cruz-Abrams Bamphrn | DIRECTOR & VP & TREASURER |
From the officer list on the latest e-filed return. Compensation is as reported there; a blank means the return carries no figure.
| MEMORIAL SLOAN KETTERING CANCER CENTERNEW YORK, NY | SUPPORTED RESEARCH ON EYE CANCER PERFORMED AT MSKCC: STUDIES ON CELL FREE DNA IN PLASMA OF RETINOBLASTOMA PATIENTS, STUDIES OF CHOROIDAL INVASION IN RETINOBLASTOMA, STUDIES OF THE USE OF INTRARTERIAL CHEMOTHERAPY IN HISTIOCYTOSIS, STUDIES ON EFFICACY AND TOXICITY OF INTRAVITREAL TOPOTECAN FOR EYE CANCER. | $161,184 | 2022 |
| MEMORIAL SLOAN KETTERING CANCER CENTERNEW YORK, NY | SUPPORTED RESEARCH ON EYE CANCER PERFORMED AT MSKCC: STUDIES ON CELL FREE DNA IN PLASMA OF RETINOBLASTOMA PATIENTS, STUDIES OF CHOROIDAL INVASION IN RETINOBLASTOMA, STUDIES OF THE USE OF INTRARTERIAL CHEMOTHERAPY IN HISTIOCYTOSIS, STUDIES ON EFFICACY AND TOXICITY OF INTRAVITREAL TOPOTECAN FOR EYE CANCER. | $157,056 | 2020 |
| MEMORIAL SLOAN KETTERING CANCER CENTERNEW YORK, NY | SUPPORTED RESEARCH ON EYE CANCER PERFORMED AT MSKCC: STUDIES ON CELL FREE DNA IN PLASMA OF RETINOBLASTOMA PATIENTS, STUDIES OF CHOROIDAL INVASION IN RETINOBLASTOMA, STUDIES OF THE USE OF INTRARTERIAL CHEMOTHERAPY IN HISTIOCYTOSIS, STUDIES ON EFFICACY AND TOXICITY OF INTRAVITREAL TOPOTECAN FOR EYE CANCER. | $56,184 | 2021 |
| MEMORIAL SLOAN KETTERING CANCER CENTERNEW YORK, NY | SUPPORTED RESEARCH ON EYE CANCER PERFORMED AT MSKCC: STUDIES ON CELL FREE DNA IN PLASMA OF RETINOBLASTOMA PATIENTS, STUDIES OF CHOROIDAL INVASION IN RETINOBLASTOMA, STUDIES OF THE USE OF INTRARTERIAL CHEMOTHERAPY IN HISTIOCYTOSIS, STUDIES ON EFFICACY AND TOXICITY OF INTRAVITREAL TOPOTECAN FOR EYE CANCER. | $56,128 | 2024 |
| 0.20 |
| $0 |
| Joseph Gold Md | DIRECTOR | 0.20 | $0 |
| Robin Cruz-Abrams | DIRECTOR | 0.20 | $0 |
Form 990 · FY2023 · period ending Dec 31, 2023IRS bulk XML
Filing id 202421379349300537
Form 990 · FY2022 · period ending Dec 31, 2022
Filing id 202301309349302280
Form 990 · FY2021 · period ending Dec 31, 2021
Filing id 202211369349304031
Form 990 · FY2020 · period ending Dec 31, 2020
Filing id 202133089349301718
Form 990 · FY2019 · period ending Dec 31, 2019
Filing id 202023189349302822
Form 990 · FY2018 · period ending Dec 31, 2018
Filing id 201912049349301056
Form 990 · FY2017 · period ending Dec 31, 2017
Filing id 201823049349300942
Form 990 · FY2016 · period ending Dec 31, 2016
Filing id 201703179349303690
Form 990 · FY2015 · period ending Dec 31, 2015
Filing id 201613169349303386
IRS filings are the source for every fact on this page. Nothing a model writes is ever a source; it can only point at a row here.